Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Jillian, Cathcart"'
Publikováno v:
Biophysica, Vol 2, Iss 3, Pp 203-220 (2022)
As 90% of cancer-patient deaths are due to metastasis, novel therapeutics that selectively target and kill metastatic cells are desperately needed. Matrix metalloproteinase-14 (MMP-14), which plays a critical role in digesting the basement membrane a
Externí odkaz:
https://doaj.org/article/97983b6ecf4b4282975594ecdafa7ef8
Autor:
Fabrice André, Yeon Hee Park, Sung-Bae Kim, Toshimi Takano, Seock-Ah Im, Giuliano Borges, Joao Paulo Lima, Sercan Aksoy, Joaquin Gavila Gregori, Michelino De Laurentiis, Giampaolo Bianchini, Rebecca Roylance, Yasuo Miyoshi, Anne Armstrong, Rajni Sinha, Manuel Ruiz Borrego, Elgene Lim, Johannes Ettl, Rinat Yerushalmi, Flora Zagouri, Francois P Duhoux, Tanja Fehm, Dhiraj Gambhire, Jillian Cathcart, Cai Wu, Changan Chu, Anton Egorov, Ian Krop
Publikováno v:
The Lancet. 401:1773-1785
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::be01883ec3cb86593318cdfe5548141c
https://doi.org/10.1016/s0140-6736(23)00725-0
https://doi.org/10.1016/s0140-6736(23)00725-0
Autor:
Sara A Hurvitz, Roberto Hegg, Wei-Pang Chung, Seock-Ah Im, William Jacot, Vinod Ganju, Joanne Wing Yan Chiu, Binghe Xu, Erika Hamilton, Srinivasan Madhusudan, Hiroji Iwata, Sevilay Altintas, Jan-Willem Henning, Giuseppe Curigliano, José Manuel Perez-Garcia, Sung-Bae Kim, Vanessa Petry, Chiun-Sheng Huang, Wei Li, Jean-Sebastien Frenel, Silvia Antolin, Winnie Yeo, Giampaolo Bianchini, Sherene Loi, Junji Tsurutani, Anton Egorov, Yali Liu, Jillian Cathcart, Shahid Ashfaque, Javier Cortés
Publikováno v:
The lancet : international edition
Background An improvement in progression-free survival was shown with trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer in the progression-free survival interim analysis of the DESTINY-Breast0
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f34ca39bb4e6f5a2f1a4d78197528f6d
https://doi.org/10.1016/s0140-6736(22)02420-5
https://doi.org/10.1016/s0140-6736(22)02420-5
Autor:
Christophe Perrin, Caleb Lee, Jillian Cathcart, Yali Liu, Toshimi Takano, Lorenzo Gianni, Rashmi K. Murthy, Cynthia R. Osborne, Sung-Bae Kim, Cristina Saura, Benoit You, Xavier Gonzàlez Farré, Ian E. Krop, Fabrice Andre, Shanu Modi, Sara A. Hurvitz, Toshinari Yamashita, Yeon Hee Park, Guy Jerusalem
DESTINY-Breast01 (NCT03248492) evaluated trastuzumab deruxtecan (T-DXd; DS-8201) in patients with heavily pretreated HER2-positive metastatic breast cancer (mBC). We present a subgroup of 24 patients with a history of treated brain metastases (BM), a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::78c6d4ee2d81e68645574e9bd1be5ffc
https://doi.org/10.1158/2159-8290.c.6549750.v1
https://doi.org/10.1158/2159-8290.c.6549750.v1
Autor:
Christophe Perrin, Caleb Lee, Jillian Cathcart, Yali Liu, Toshimi Takano, Lorenzo Gianni, Rashmi K. Murthy, Cynthia R. Osborne, Sung-Bae Kim, Cristina Saura, Benoit You, Xavier Gonzàlez Farré, Ian E. Krop, Fabrice Andre, Shanu Modi, Sara A. Hurvitz, Toshinari Yamashita, Yeon Hee Park, Guy Jerusalem
Supplementary Data from Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::078d93ee5110d3355a15165f153f2e5c
https://doi.org/10.1158/2159-8290.22541826
https://doi.org/10.1158/2159-8290.22541826
Autor:
Javier, Cortés, Sung-Bae, Kim, Wei-Pang, Chung, Seock-Ah, Im, Yeon Hee, Park, Roberto, Hegg, Min Hwan, Kim, Ling-Ming, Tseng, Vanessa, Petry, Chi-Feng, Chung, Hiroji, Iwata, Erika, Hamilton, Giuseppe, Curigliano, Binghe, Xu, Chiun-Sheng, Huang, Jee Hyun, Kim, Joanne W Y, Chiu, Jose Luiz, Pedrini, Caleb, Lee, Yali, Liu, Jillian, Cathcart, Emarjola, Bako, Sunil, Verma, Sara A, Hurvitz, Gail, Wright
Publikováno v:
New England Journal of Medicine. 386:1143-1154
Trastuzumab emtansine is the current standard treatment for patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer whose disease progresses after treatment with a combination of anti-HER2 antibodies and a taxa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b546e51ec290c6b7ea098e477d903539
https://doi.org/10.1056/nejmoa2115022
https://doi.org/10.1056/nejmoa2115022
Autor:
Guy Jerusalem, Yeon Hee Park, Toshinari Yamashita, Sara A. Hurvitz, Shanu Modi, Fabrice Andre, Ian E. Krop, Xavier Gonzàlez Farré, Benoit You, Cristina Saura, Sung-Bae Kim, Cynthia R. Osborne, Rashmi K. Murthy, Lorenzo Gianni, Toshimi Takano, Yali Liu, Jillian Cathcart, Caleb Lee, Christophe Perrin
Publikováno v:
Scientia
Cancer discovery, vol 12, iss 12
Cancer discovery, vol 12, iss 12
DESTINY-Breast01 (NCT03248492) evaluated trastuzumab deruxtecan (T-DXd; DS-8201) in patients with heavily pretreated HER2-positive metastatic breast cancer (mBC). We present a subgroup of 24 patients with a history of treated brain metastases (BM), a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e586461f6af1bc62620aa680c5760dbf
https://pubmed.ncbi.nlm.nih.gov/36255231
https://pubmed.ncbi.nlm.nih.gov/36255231
Publikováno v:
The New England journal of medicine. 386(24)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5b6605e4a11f44120b9f24faf98e0a6d
https://pubmed.ncbi.nlm.nih.gov/35704495
https://pubmed.ncbi.nlm.nih.gov/35704495
Autor:
Ian Krop, Yeon H. Park, Sung-Bae Kim, Giuliano Borges, Sercan Aksoy, Joaquin Gavila Gregori, Rebecca Roylance, Elgene Lim, Rinat Yerushalmi, Flora Zagouri, Francois P. Duhoux, Tanja Fehm, Toshimi Takano, Anton Egorov, Iris Wu, Jillian Cathcart, Changan Chu, Fabrice Andre
Publikováno v:
Cancer Research. 83:GS2-01
In DESTINY-Breast01 (NCT03248492) and DESTINY-Breast03 (NCT03529110), trastuzumab deruxtecan (T-DXd) demonstrated unprecedented activity in patients (pts) with HER2+ (immunohistochemistry 3+; immunohistochemistry 2+/in situ hybridization+) advanced m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3fa0d913806429de67d53cfaba89ce2b
https://doi.org/10.1158/1538-7445.sabcs22-gs2-01
https://doi.org/10.1158/1538-7445.sabcs22-gs2-01
Autor:
Sara Hurvitz, Roberto Hegg, Wei-Pang Chung, Seock-Ah Im, William Jacot, Vinod Ganju, Joanne Win Yang Chiu, Binghe Xu, Erika Hamilton, Srinivasan Madhusudan, Hiroji Iwata, Sevilay Altintas, Jan-Willem Henning, Giuseppe Curigliano, José Manuel Pérez-García, Anton Egorov, Yali Liu, Jillian Cathcart, Shahid Ashfaque, Javier Cortés
Publikováno v:
Cancer Research. 83:GS2-02
Background: Trastuzumab deruxtecan (T-DXd) is approved in the United States and European Union for use in patients (pts) with HER2+ unresectable/metastatic breast cancer (mBC) after ≥1 prior anti–HER2 regimen(s). Approval was based on the randomi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9a0aec23dcbc826d3e1f1a172c462460
https://doi.org/10.1158/1538-7445.sabcs22-gs2-02
https://doi.org/10.1158/1538-7445.sabcs22-gs2-02